CVKD — Cadrenal Therapeutics Share News
0.000.00%
Last trade - 00:00Cadrenal Therapeutics falls on $7.5 mln private placement
Brief: Cadrenal Therapeutics Provides Q1 Corporate Update
Cadrenal Therapeutics up as blood disease drug gets FDA's fast-track tag
Brief: Cadrenal Therapeutics Granted FDA Fast Track Designation For Tecarfarin For Prevention Of Systemic Thromboembolism Of Cardiac Origin In Patients With End-Stage Renal Disease And Atrial Fibrillation
Brief: Cadrenal Therapeutics Announces Pricing Of Initial Public Offering